250 related articles for article (PubMed ID: 22120693)
1. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
Bilusic M; Gulley JL
Cancer Immunol Immunother; 2012 Jan; 61(1):109-17. PubMed ID: 22120693
[TBL] [Abstract][Full Text] [Related]
2. Improved endpoints for cancer immunotherapy trials.
Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
[TBL] [Abstract][Full Text] [Related]
3. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
4. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
5. Correlates of immune and clinical activity of novel cancer vaccines.
van der Burg SH
Semin Immunol; 2018 Oct; 39():119-136. PubMed ID: 29709421
[TBL] [Abstract][Full Text] [Related]
6. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
7. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
Simon RM; Steinberg SM; Hamilton M; Hildesheim A; Khleif S; Kwak LW; Mackall CL; Schlom J; Topalian SL; Berzofsky JA
J Clin Oncol; 2001 Mar; 19(6):1848-54. PubMed ID: 11251017
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of active cancer immunotherapy.
Nawrocki S; Mackiewicz A
Expert Opin Investig Drugs; 2007 Aug; 16(8):1137-41. PubMed ID: 17685864
[TBL] [Abstract][Full Text] [Related]
10. Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.
Castonguay V; Wilson MK; Diaz-Padilla I; Wang L; Oza AM
Cancer; 2015 Feb; 121(3):413-22. PubMed ID: 25278038
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic cancer vaccines: current status and moving forward.
Schlom J
J Natl Cancer Inst; 2012 Apr; 104(8):599-613. PubMed ID: 22395641
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in therapeutic cancer vaccines.
Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
[TBL] [Abstract][Full Text] [Related]
14. Trends in endpoint selection in clinical trials of advanced breast cancer.
Song SY; Seo H; Kim G; Kim AR; Kim EY
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2403-13. PubMed ID: 27586374
[TBL] [Abstract][Full Text] [Related]
15. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
16. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
18. Cell based cancer vaccines: regulatory and commercial development.
Copier J; Ward S; Dalgleish A
Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
[TBL] [Abstract][Full Text] [Related]
19. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
Hurvitz SA; Timmerman JM
Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.
Ascierto PA; Long GV
Lancet Oncol; 2016 Aug; 17(8):1037-1039. PubMed ID: 27324281
[No Abstract] [Full Text] [Related]
[Next] [New Search]
